163 related articles for article (PubMed ID: 31446991)
1. Establishing a histology-specific biologically effective dose threshold for lung stereotactic ablative radiotherapy (SABR): Is ≥100 Gy
Abel S; Hasan S; Verma V; Weksler B; Colonias A; Horne ZD; Wegner RE
Lung Cancer; 2019 Sep; 135():169-174. PubMed ID: 31446991
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic ablative radiotherapy (SABR) in early stage non-small cell lung cancer: Comparing survival outcomes in adenocarcinoma and squamous cell carcinoma.
Abel S; Hasan S; White R; Schumacher L; Finley G; Colonias A; Wegner RE
Lung Cancer; 2019 Feb; 128():127-133. PubMed ID: 30642444
[TBL] [Abstract][Full Text] [Related]
3. Feasible Optimization of Stereotactic Ablative Radiotherapy Dose by Tumor Size for Stage I Non-small-cell Lung Cancer.
Lee S; Song SY; Kim SS; Choi W; Je HU; Back GM; Cho B; Jeong SY; Choi EK
Clin Lung Cancer; 2018 Mar; 19(2):e253-e261. PubMed ID: 29196082
[TBL] [Abstract][Full Text] [Related]
4. Nomogram Predicting Overall Survival Benefit of Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.
Jacobs CD; Mehta K; Gao J; Wang X; Salama JK; Kelsey CR; Torok JA
Clin Lung Cancer; 2022 Mar; 23(2):177-184. PubMed ID: 34301453
[TBL] [Abstract][Full Text] [Related]
5. Histology-driven hypofractionated radiation therapy schemes for early-stage lung adenocarcinoma and squamous cell carcinoma.
Liu F; Farris MK; Ververs JD; Hughes RT; Munley MT
Radiother Oncol; 2024 Jun; 195():110257. PubMed ID: 38548113
[TBL] [Abstract][Full Text] [Related]
6. Assessment of precision irradiation in early non-small cell lung cancer and interstitial lung disease (ASPIRE-ILD): study protocol for a phase II trial.
Palma DA; Chen H; Bahig H; Gaede S; Harrow S; Laba JM; Qu XM; Rodrigues GB; Yaremko BP; Yu E; Louie AV; Dhaliwal I; Ryerson CJ
BMC Cancer; 2019 Dec; 19(1):1206. PubMed ID: 31829203
[TBL] [Abstract][Full Text] [Related]
7. A comparison between accelerated hypofractionation and stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer (NSCLC): Results of a propensity score-matched analysis.
Chiang A; Thibault I; Warner A; Rodrigues G; Palma D; Soliman H; Jain S; Poon I; Cheung P
Radiother Oncol; 2016 Mar; 118(3):478-84. PubMed ID: 26795773
[TBL] [Abstract][Full Text] [Related]
8. Survival analysis after stereotactic ablative radiotherapy for early stage non-small cell lung cancer: a single-institution cohort study.
Resova K; Knybel L; Parackova T; Rybar M; Cwiertka K; Cvek J
Radiat Oncol; 2024 Apr; 19(1):50. PubMed ID: 38637844
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic body radiation therapy for medically inoperable early-stage lung cancer: Tata Memorial Hospital perspective and practice recommendations.
Agarwal JP; Pilar A; Mummudi N; Gupta M; Laskar SG; Pathak RS; Tibdewal AR; Kinhikar R; Ghadi Y; Tandon S; Purandare N; Prabhash K; Patil V
Indian J Cancer; 2020; 57(1):18-24. PubMed ID: 31929233
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic Ablative Body Radiotherapy Versus Radical Radiotherapy: Comparing Real-World Outcomes in Stage I Lung Cancer.
Phillips I; Sandhu S; Lüchtenborg M; Harden S
Clin Oncol (R Coll Radiol); 2019 Oct; 31(10):681-687. PubMed ID: 31377081
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
Stahl JM; Ross R; Harder EM; Mancini BR; Soulos PR; Finkelstein SE; Shafman TD; Dosoretz AP; Evans SB; Husain ZA; Yu JB; Gross CP; Decker RH
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1011-1020. PubMed ID: 27869080
[TBL] [Abstract][Full Text] [Related]
12. Higher biologically effective dose is associated with improved survival in patients with squamous cell carcinoma of the lung treated with stereotactic body radiation therapy.
Parzen JS; Almahariq MF; Quinn TJ; Siddiqui ZA; Thompson AB; Guerrero T; Lee K; Stevens C; Grills IS
Radiother Oncol; 2021 Jul; 160():25-31. PubMed ID: 33892021
[TBL] [Abstract][Full Text] [Related]
13. Predicting 5-Year Progression and Survival Outcomes for Early Stage Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy: Development and Validation of Robust Prognostic Nomograms.
Kang J; Ning MS; Feng H; Li H; Bahig H; Brooks ED; Welsh JW; Ye R; Miao H; Chang JY
Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):90-99. PubMed ID: 31586665
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic ablative radiation therapy versus conventionally fractionated radiation therapy for stage I small cell lung cancer.
Verma V; Hasan S; Wegner RE; Abel S; Colonias A
Radiother Oncol; 2019 Feb; 131():145-149. PubMed ID: 30773182
[TBL] [Abstract][Full Text] [Related]
15. Safety and Effectiveness of Stereotactic Ablative Radiotherapy for Ultra-Central Lung Lesions: A Systematic Review.
Chen H; Laba JM; Zayed S; Boldt RG; Palma DA; Louie AV
J Thorac Oncol; 2019 Aug; 14(8):1332-1342. PubMed ID: 31075543
[TBL] [Abstract][Full Text] [Related]
16. Histology significantly affects recurrence and survival following SBRT for early stage non-small cell lung cancer.
Baine MJ; Verma V; Schonewolf CA; Lin C; Simone CB
Lung Cancer; 2018 Apr; 118():20-26. PubMed ID: 29571997
[TBL] [Abstract][Full Text] [Related]
17. Increasing radiation therapy dose is associated with improved survival in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer.
Koshy M; Malik R; Weichselbaum RR; Sher DJ
Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):344-50. PubMed ID: 25636759
[TBL] [Abstract][Full Text] [Related]
18. Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Stage III NSCLC.
Schild SE; Pang HH; Fan W; Stinchcombe TE; Vokes EE; Ramalingam SS; Bradley JD; Kelly K; Wang X
J Thorac Oncol; 2018 Aug; 13(8):1171-1182. PubMed ID: 29689435
[TBL] [Abstract][Full Text] [Related]
19. Five-year Long-term Outcomes of Stereotactic Body Radiation Therapy for Operable Versus Medically Inoperable Stage I Non-small-cell Lung Cancer: Analysis by Operability, Fractionation Regimen, Tumor Size, and Tumor Location.
Schonewolf CA; Heskel M; Doucette A; Singhal S; Frick MA; Xanthopoulos EP; Corradetti MN; Friedberg JS; Pechet TT; Christodouleas JP; Levin W; Berman A; Cengel KA; Verma V; Hahn SM; Kucharczuk JC; Rengan R; Simone CB
Clin Lung Cancer; 2019 Jan; 20(1):e63-e71. PubMed ID: 30337269
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic body radiation therapy for stage I non-small cell lung cancer: The importance of treatment planning algorithm and evaluation of a tumor control probability model.
Ohri N; Tomé W; Kalnicki S; Garg M
Pract Radiat Oncol; 2018; 8(2):e33-e39. PubMed ID: 29233523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]